

TEST CHANGE

Autoimmune Movement Disorder Panel, Serum 3006206, AIMDS

3000200, AIMDS	
Specimen Requirements:	
Patient Preparation:	
Collect:	Serum separator tube (SST)
Specimen Preparation:	Separate from cells ASAP or within 2 hours of collection. Transfer three 1 mL serum aliquots to ARUP standard transport tubes. (Min: 0.5 mL/aliquot)
Transport Temperature:	Frozen
Unacceptable Conditions:	Amniotic fluid, ocular fluid, peritoneal fluid, synovial fluid, CSF, or plasma. Contaminated, hemolyzed, icteric, or lipemic specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month 30 days (avoid repeated freeze/thaw cycles)
Methodology:	Semi-Quantitative Cell-Based Indirect Fluorescent Antibody/Semi-Quantitative Indirect Fluorescent Antibody (IFA)/Qualitative Immunoblot/Semi-Quantitative Enzyme- Linked Immunosorbent Assay (ELISA)/Quantitative Radioimmunoassay (RIA)
Performed:	Varies
Reported:	3-10 days
Note:	If NMDA antibody IgG is positive, then titer will be performed. Additional charges apply. If CV2.1 antibody IgG is positive, then titer will be added. Additional charges apply. PCCA/ANNA antibody IgG is screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri,

Yo, and Tr/DNER) IgG by Immunoblot will be performed. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be performed. Additional charges apply. If LGI1 antibody IgG is positive, then titer will be added. Additional charges apply. If CASPR2 antibody IgG is positive, then titer will be added. Additional charges apply. If DPPX antibody IgG by IFA is positive, then titer will be added.

Effective Date: February 20, 2024



Additional charges apply. If AMPA antibody IgG is positive, then titer will be added. Additional charges apply. If GABA-BR antibody IgG is positive, then titer will be added. Additional charges apply. If GABA-AR antibody IgG by IFA is positive, then titer will be added. Additional charges apply. If mGluR1 antibody IgG by IFA is positive, then titer will be added. Additional charges apply. If ITPR1 antibody IgG by IFA is positive, then titer will be added. Additional charges apply. If IgLON5 antibody IgG by IFA is positive, then titer will be added. Additional charges apply.

Effective Date: February 20, 2024

CPT Codes: 86341; 86596; 84182 x2; 86255 x12; if reflexed add 84182 x4;

86256 per titer

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Refer to report.

Component	Interpretation
P/Q-Type	0.0-24.5 pmol/L
Voltage-Gated	Negative 24.6-
Calcium Channel	45.6 pmol/L
(VGCC) Antibody	Indeterminate
	45.7 pmol/L or
	greater Positive

Reference Interval:

Test Number	Components	Reference Interval
	CV2-1 Ab IgG CBA-IFA Screen, Serum	Less than 1:100
	Neuronal Antibody (Amphiphysin)	Negative
	Glutamic Acid Decarboxylase Antibody	0.0-5.0 IU/mL
	Purkinje Cell/Neuronal Nuclear IgG Scrn	None Detected
	NMDA Receptor Ab IgG CBA-IFA, Serum	Less than 1:10
	P/Q-Type Calcium Channel Antibody	24.5 pmol/L or less
	SOX1 Antibody, IgG by Immunoblot, Serum	Negative
	AMPA Receptor Ab IgG CBA-IFA Scrn, Serum	Less than 1:10
	GABA-BR Ab IgG CBA-IFA Scrn, Ser	Less than 1:10
	DPPX Ab IgG CBA-IFA Screen, Serum	Less than 1:10
	GABA-AR Ab IgG CBA-IFA Screen, Serum	Less than 1:10
	IgLON5 Ab IgG CBA-IFA Screen, Serum	Less than 1:10
	mGluR1 Ab IgG CBA-IFA Screen, Serum	Less than 1:10
	ITPR1 Ab IgG CBA-IFA Screen, Serum	Less than 1:10
	CASPR2 Ab IgG CBA-IFA Screen, Serum	Less than 1:10



LGI1 Ab IgG CBA-IFA Screen, Serum Less than 1:10

Effective Date: February 20, 2024

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.